Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
C$2.44
+19.0%
C$2.08
C$1.02
C$30.90
C$105.06M1.365,447 shs9,312 shs
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$262.23
+3.6%
$236.33
$211.43
$387.99
$7.14B0.95335,848 shs130,276 shs
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
N/A16.6540 shsN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$5.32
-0.5%
$4.29
$2.76
$6.00
$250.51M0.4115,420 shs3,490 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-8.07%+70.83%-14.58%-31.21%-93.17%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
+0.81%+0.86%+12.00%+8.87%-7.98%
ERGO
Entia Biosciences
0.00%0.00%0.00%0.00%0.00%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-1.66%+8.87%+13.98%+66.88%+1.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.5974 of 5 stars
2.45.00.04.22.92.51.9
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.2715 of 5 stars
3.33.00.00.02.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
4.00
Strong BuyN/AN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.75
Moderate Buy$324.2523.65% Upside
ERGO
Entia Biosciences
0.00
N/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.0050.52% Upside

Current Analyst Ratings Breakdown

Latest NBTX, BIO, APS, and ERGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $245.00
5/2/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$355.00 ➝ $310.00
5/2/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$400.00 ➝ $350.00
5/2/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$409.00 ➝ $392.00
4/17/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$320.00 ➝ $270.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/AN/AC$1.53 per share1.60C($0.92) per shareN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.57B2.78$10.87 per share24.13$234.52 per share1.12
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$11.61M-21.58N/AN/A($1.51) per share-3.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-C$154.69M-C$5.02N/AN/AN/A1,017.48%-136.29%N/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$1.84B-$76.20N/A21.06N/A-85.16%4.32%3.03%7/30/2025 (Estimated)
ERGO
Entia Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/A9/16/2025 (Estimated)

Latest NBTX, BIO, APS, and ERGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$1.98N/AN/AN/AN/AN/A
5/1/2025Q1 2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$1.73$2.54+$0.81$2.29$573.01 million$585.40 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/A0.39%N/AN/AN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-117.37
1.05
5.41
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.18
5.99
4.43
ERGO
Entia Biosciences
N/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04

Institutional Ownership

CompanyInstitutional Ownership
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
15.10%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
ERGO
Entia Biosciences
N/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%

Insider Ownership

CompanyInsider Ownership
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
17.11%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.06%
ERGO
Entia Biosciences
28.30%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
3143.06 millionN/ANot Optionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
7,70027.21 million22.57 millionOptionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.13 million45.51 millionNot Optionable

Recent News About These Companies

Nanobiotix price target lowered to $8 from $12 at Guggenheim
Nanobiotix (NBTX) Gets a Hold from UBS
Nanobiotix amends global licensing agreement with Janssen Pharmaceutica

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aptose Biosciences stock logo

Aptose Biosciences TSE:APS

C$2.44 +0.39 (+19.02%)
As of 12:00 PM Eastern

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Bio-Rad Laboratories stock logo

Bio-Rad Laboratories NYSE:BIO

$262.23 +9.16 (+3.62%)
As of 01:05 PM Eastern

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Entia Biosciences OTCMKTS:ERGO

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$5.32 -0.03 (-0.47%)
As of 01:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.